US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by BioAge Labs, Inc.

< Previous 1 2 Next >
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Announces Proposed Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
News headline image
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
< Previous 1 2 Next >